Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Luteinizing-hormone releasing hormone therapy and the risk of death from Alzheimer disease.

D'Amico AV, Braccioforte MH, Moran BJ, Chen MH.

Alzheimer Dis Assoc Disord. 2010 Jan-Mar;24(1):85-9.

PMID:
20556875
2.

Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.

Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1439-44. doi: 10.1016/j.ijrobp.2009.03.034. Epub 2009 Jun 18.

PMID:
19540066
3.

Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.

Hall MC, Fritzsch RJ, Sagalowsky AI, Ahrens A, Petty B, Roehrborn CG.

Urology. 1999 May;53(5):898-902; discussion 902-3.

PMID:
10223480
4.

Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death.

D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW.

Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):10-5. doi: 10.1016/j.ijrobp.2008.10.082. Epub 2009 Apr 22.

PMID:
19395184
5.

Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy.

Dosoretz AM, Chen MH, Salenius SA, Ross RH, Dosoretz DE, Katin MJ, Mantz C, Nakfoor BM, D'Amico AV.

Cancer. 2010 Feb 15;116(4):837-42. doi: 10.1002/cncr.24750.

6.

Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.

Chen RC, Sadetsky N, Chen MH, Carroll PR, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):36-9. doi: 10.1016/j.ijrobp.2008.10.059. Epub 2009 Feb 23.

PMID:
19233568
7.

Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy.

Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):147-52. doi: 10.1016/j.ijrobp.2009.04.085. Epub 2009 Sep 8.

PMID:
19744800
9.

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.

Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR.

J Natl Cancer Inst. 2007 Oct 17;99(20):1516-24. Epub 2007 Oct 9.

PMID:
17925537
10.

Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up.

Akaza H, Homma Y, Usami M, Hirao Y, Tsushima T, Okada K, Yokoyama M, Ohashi Y, Aso Y; Prostate Cancer Study Group.

BJU Int. 2006 Sep;98(3):573-9.

11.

Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.

Bong GW, Clarke HS Jr, Hancock WC, Keane TE.

Urology. 2008 Jun;71(6):1177-80. doi: 10.1016/j.urology.2007.09.066. Epub 2008 Feb 15.

PMID:
18279929
12.

Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.

Moreau JP, Delavault P, Blumberg J.

Clin Ther. 2006 Oct;28(10):1485-508. Review. Erratum in: Clin Ther. 2006 Nov;28(11):1970.

PMID:
17157109
14.

Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).

Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR; CaPSURE Investigators.

Cancer. 2006 Apr 15;106(8):1708-14.

15.
16.
17.

Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.

Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D'Amico AV.

Urology. 2008 Jan;71(1):136-40. doi: 10.1016/j.urology.2007.08.028.

PMID:
18242382
18.
19.

p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).

D'Amico AV, Halabi S, Vollmer R, Loffredo M, McMahon E, Sanford B, Archer L, Vogelzang NJ, Small EJ, Kantoff PW; Cancer and Leukemia Group B.

Urology. 2008 May;71(5):933-7. doi: 10.1016/j.urology.2007.11.005. Epub 2008 Feb 21.

PMID:
18291508
20.

Failure to achieve a PSA level <or=1 ng/mL after neoadjuvant LHRHa therapy predicts for lower biochemical control rate and overall survival in localized prostate cancer treated with radiotherapy.

Mitchell DM, McAleese J, Park RM, Stewart DP, Stranex S, Eakin RL, Houston RF, O'Sullivan JM.

Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1467-71. Epub 2007 Aug 8.

PMID:
17689886

Supplemental Content

Support Center